Recent research and development of DYRK1A inhibitors
Authors:
- Liyun ZhaoLZLiyun Zhao
- Xuan XiongXXXuan Xiong
- Li LiuLLLi Liu
- Qi LiangQLQi Liang
- Rongsheng TongRTRongsheng Tong
- Xuanlin FengXFXuanlin Feng
- Lan BaiLBLan Bai
- Jianyou ShiJSJianyou Shi
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Chinese Chemical Letters
- Vol. 33 (4) , 1841-1849
Abstract
No abstract availableKeywords
This publication has 128 references indexed in Scilit:
- Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate RecognitionStructure, 2013
- Abnormal brain synchrony in Down SyndromeNeuroImage: Clinical, 2013
- A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid “Harmine”Asian Pacific Journal of Tropical Biomedicine, 2012
- Molecular basis of pharmacotherapies for cognition in Down syndromeTrends in Pharmacological Sciences, 2010
- Targeting protein kinases in central nervous system disordersNature Reviews Drug Discovery, 2009
- Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1Nature, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21Nature, 2006
- Green tea catechins as brain‐permeable, natural iron chelators‐antioxidants for the treatment of neurodegenerative disordersMolecular Nutrition & Food Research, 2006